6QC.F TOWA PHARMA. CO.
- Market cap
- EUR 916M
- P/E
- 19.4x
- P/B
- 0.92x
- ROE
- 12.1%
- Dividend yield
- 2.36%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 6QC.F undervalued?
Graham number6QC.F trades 10.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TOWA PHARMA. CO. fundamental analysis
No fundamental analysis for TOWA PHARMA. CO. yet.
TOWA PHARMA. CO. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TOWA PHARMA. CO.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT se…
Full company profileTOWA PHARMA. CO. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TOWA PHARMA. CO. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 166B | 209B | 228B | 260B | 274B | 286B |
| Gross Profit | 70.2B | 72.7B | 81.4B | 94.7B | 99.1B | 104B |
| Operating Income | 19.2B | 5.51B | 17.6B | 23.2B | 23.1B | 26.1B |
| EBITDA | - | 24.6B | 43.3B | 48.1B | 38.3B | 34.3B |
| Net Income | 15.9B | 2.20B | 16.2B | 19.0B | 5.25B | 22.1B |
| EPS | 323 | 45 | 329 | 386 | 107 | 449 |
| Balance Sheet | ||||||
| Total Assets | 332B | 371B | 431B | 471B | 475B | 481B |
| Total Liabilities | 200B | 234B | 275B | 299B | 297B | 298B |
| Shareholders' Equity | 132B | 137B | 156B | 172B | 178B | 182B |
| Cash & Short-term Investments | 32.8B | 24.3B | 29.7B | 45.5B | 45.3B | 42.2B |
| Cash Flow | ||||||
| Operating Cash Flow | 22.1B | 2.54B | 8.21B | 23.4B | 30.4B | - |
| Capital Expenditure | 13.6B | 30.5B | 39.3B | 31.2B | 24.1B | 0.00 |
| Free Cash Flow | 8.55B | -27.9B | -31.1B | -7.82B | 6.30B | - |
| Ratios | ||||||
| ROE | 12.0% | 1.6% | 10.4% | 11.1% | 2.9% | 12.1% |
| ROA | 4.8% | 0.6% | 3.8% | 4.0% | 1.1% | 4.6% |
| Net Profit Margin | 9.6% | 1.1% | 7.1% | 7.3% | 1.9% | 7.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
TOWA PHARMA. CO. dividends
- Dividend yield
- 2.36%
- Forward dividend
- 0.44 EUR
- Payout ratio
- 75.0%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 3.94B | 80 | 75.0% |
| 2025 | JPY 2.95B | 60 | 15.6% |
| 2024 | JPY 2.95B | 60 | 18.3% |
| 2023 | JPY 3.10B | 63 | 140.8% |
| 2022 | JPY 2.41B | 49 | 15.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns TOWA PHARMA. CO.
- Insiders 48.16%
- Institutions 20.79%
- Public & others 31.05%
- Shares outstanding 49.2M
- Free float 24.5M
TOWA PHARMA. CO. company profile
- Company name
- TOWA PHARMA. CO.
- Ticker
- 6QC.F
- ISIN
- JP3623150004
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,923
- Fiscal year end
- March
- Address
- 2-11, Shinbashi-cho, Kadoma, Japan, 571-8580
- Phone
- 81 6 6900 9100
- Website
- towayakuhin.co.jp
About TOWA PHARMA. CO.
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs. In addition, it is involved in research and development and production of active pharmaceutical ingredients, intermediates, and support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Kadoma, Japan.
TOWA PHARMA. CO. management
10- Mr. Itsuro YoshidaPresident & Representative Director · born 1951
- Shiro HatagamiExecutive Officer and Head of Accounting & Finance Division
- Tetsuo YamashitaOperating Officer, Plant Manager of Okayama Plant & GM of Administration Department
- Mr. Masaji MorikawaOperating Officer & Division Manager of Sales and Marketing Division
- Shigeki FujitaOperating Officer & GM of Human Resource Development Center
- Yutaka OkudaSenior Executive Officer & Head of R&D and Fundamental Technology
- Mr. Masao TanakaDirector · born 1954
- Mr. Osamu Uchikawa Ph.D.Senior MD & Director · born 1958
- Mr. Masaaki TakeyasuMD & Director · born 1964
- Mr. Takahiko Taniguchi Ph.D.Senior Executive Officer & Head of Reliability Assurance